Chemomab Therapeutics Ltd. (CMMB) Latest Filing Signal

Latest Filing: 20-F  |  Filed Mar 23, 2026

Cross-checked across multiple AI analysts and grounded in the latest SEC filing.

powered by: earningsVibe.ai

Question:
What is the latest filing signal for Chemomab Therapeutics Ltd.?
Answer:
Based on earningsVibe SuperAnalyst™ synthesis of the latest 20-F, Chemomab Therapeutics Ltd.'s filing signal continuing negative.
earningsVibe SuperAnalyst™ Verdict: CONTINUING NEGATIVE

Signal Performance — Stock Price Since Filing

30-Day Change
Pending
from filing date
60-Day Change
Pending
from filing date

Underlying analyst views from Perplexity, Gemini, Claude, and ChatGPT

PERPLEXITY
Continuing Positive
GEMINI
Continuing Negative
CLAUDE
Turned Positive
CHATGPT
Continuing Negative

Unlock the Full Filing Analysis

See full earningsSig™ and risksSig™ analysis across 5,000+ companies

Get Started Free →

No credit card required

Question:
What does Chemomab Therapeutics Ltd. actually do?
Answer:
Chemomab Therapeutics Ltd. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for fibrotic and inflammatory diseases. The company's lead product candidate, nebokitug (CM-101), is a monoclonal antibody designed to target and block the soluble protein CCL24, which plays a key role in promoting fibrosis and inflammation. Nebokitug has demonstrated potential in treating rare diseases such as primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc), with positive Phase 2 clinical trial results reported for PSC. Chemomab has aligned with the FDA on a Phase 3 trial design for PSC and is exploring nebokitug's potential in other fibrotic conditions like MASH. The company is headquartered in Tel Aviv, Israel.
Question:
What are Chemomab Therapeutics Ltd.'s revenue drivers?
Answer:
The company has not generated any revenue from product sales to date and does not expect to in the near future. Future revenue is anticipated from the potential commercialization of its product candidates, particularly nebokitug, if regulatory approvals are obtained.

Cut through noisy SEC filings to find the signal faster

Source-grounded filing intelligence with one-click links back to the filing, so you can move faster and verify everything at the source.

Get Started Free →

No credit card required